Hemostatic agents for bleeding: Recombinant-activated factor VII and beyond

Seminars in Thrombosis and Hemostasis

Volumn 41, Issue 3, 2015, Pages 342-347

  Franchini, Massimo ^a   Crestani, Silvia ^a   Frattini, Francesco ^a   Sissa, Cinzia ^a   Bonfanti, Carlo ^a  

^a CARLO POMA HOSPITAL   (Italy)

Author keywords

bleeding; new oral anticoagulants; prothrombin complex concentrates; rFVIIa; vitamin K antagonists; warfarin

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7A; HEMOSTATIC AGENT; PROTHROMBIN; PROTHROMBIN COMPLEX CONCENTRATES; RECOMBINANT FVIIA; RECOMBINANT PROTEIN; VITAMIN K GROUP;

ANIMAL; ANTAGONISTS AND INHIBITORS; HEMORRHAGE; HEMOSTASIS; HUMAN; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; FACTOR VIIA; HEMORRHAGE; HEMOSTASIS; HEMOSTATICS; HUMANS; PROTHROMBIN; RECOMBINANT PROTEINS; VITAMIN K;

EID: 84928017919     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0034-1381234     Document Type: Article

References (73)

1. Mannucci P. M., Levi M. Prevention and treatment of major blood loss. N Engl J Med: 2007; 356 22 2301 2311
2. Schulman S. Pharmacologic tools to reduce bleeding in surgery. Hematology (Am Soc Hematol Educ Program): 2012; 2012 517 521
3. Kozek-Langenecker S. A., Afshari A., Albaladejo P., et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol: 2013; 30 6 270 382
4. Franchini M., Lippi G. Recent improvements in the clinical treatment of coagulation factor inhibitors. Semin Thromb Hemost: 2009; 35 8 806 813
5. Franchini M., Mannucci P. M. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol: 2011; 72 4 553 562
6. Franchini M. The modern treatment of haemophilia: a narrative review. Blood Transfus: 2013; 11 2 178 182
7. Franchini M., Coppola A., Tagliaferri A., Lippi G. FEIBA versus NovoSeven in hemophilia patients with inhibitors. Semin Thromb Hemost: 2013; 39 7 772 778
8. Franchini M., Lippi G. Recombinant activated factor VII: mechanisms of action and current indications. Semin Thromb Hemost: 2010; 36 5 485 492
9. Franchini M., Lippi G. Acquired factor VIII inhibitors. Blood: 2008; 112 2 250 255
10. Coppola A., Favaloro E. J., Tufano A., Di Minno M. N., Cerbone A. M., Franchini M. Acquired inhibitors of coagulation factors: part I-acquired hemophilia A. Semin Thromb Hemost: 2012; 38 5 433 446
11. Hoffman M., Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. J Thromb Haemost: 2012; 10 8 1478 1485
12. ten Cate H., Bauer K. A., Levi M., et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest: 1993; 92 3 1207 1212
13. Roberts H. R., Monroe D. M., White G. C. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood: 2004; 104 13 3858 3864
14. Butenas S., Brummel K. E., Branda R. F., Paradis S. G., Mann K. G. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood: 2002; 99 3 923 930
15. Lisman T., Mosnier L. O., Lambert T., et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood: 2002; 99 1 175 179
16. Hedner U., Lee C. A. First 20 years with recombinant FVIIa (NovoSeven). Haemophilia: 2011; 17 1 e172 e182
17. Franchini M., Zaffanello M., Veneri D. Recombinant factor VIIa. An update on its clinical use. Thromb Haemost: 2005; 93 6 1027 1035
18. Franchini M. Recombinant factor VIIa: a review on its clinical use. Int J Hematol: 2006; 83 2 126 138
19. Dutton R. P., Parr M., Tortella B. J., et al. CONTROL Study Group. Recombinant activated factor VII safety in trauma patients: results from the CONTROL trial. J Trauma: 2011; 71 1 12 19
20. Boffard K. D., Riou B., Warren B., et al. NovoSeven Trauma Study Group. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma: 2005; 59 1 8 15, discussion 15-18
21. Yank V., Tuohy C. V., Logan A. C., et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med: 2011; 154 8 529 540
22. Levi M., Levy J. H., Andersen H. F., Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med: 2010; 363 19 1791 1800
23. Simpson E., Lin Y., Stanworth S., Birchall J., Doree C., Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev: 2012; 3 CD005011
24. Franchini M., Lippi G., Franchi M. The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage. BJOG: 2007; 114 1 8 15
25. Franchini M., Franchi M., Bergamini V., Salvagno G. L., Montagnana M., Lippi G. A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage. Semin Thromb Hemost: 2008; 34 1 104 112
26. Franchini M., Franchi M., Bergamini V., et al. The use of recombinant activated FVII in postpartum hemorrhage. Clin Obstet Gynecol: 2010; 53 1 219 227
27. Ahonen J. The role of recombinant activated factor VII in obstetric hemorrhage. Curr Opin Anaesthesiol: 2012; 25 3 309 314
28. WHO WHO recommendations for the prevention and treatment of postpartum haemorrhage. http://apps.who.int/iris/bitstream/10665/75411/1/9789241548502-eng. pdf. Published 2012
29. Hellstern P. Production and composition of prothrombin complex concentrates: correlation between composition and therapeutic efficiency. Thromb Res: 1999; 95 4 01 S7 S12
30. Franchini M., Lippi G. Prothrombin complex concentrates: an update. Blood Transfus: 2010; 8 3 149 154
31. Franchini M., Liumbruno G. M., Lanzoni M., et al. Clinical use and the Italian demand for prothrombin complex concentrates. Blood Transfus: 2013; 11 04 s94 s100
32. Schöchl H., Nienaber U., Hofer G., et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care: 2010; 14 2 R55
33. Schöchl H., Nienaber U., Maegele M., et al. Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. Crit Care: 2011; 15 2 R83
34. Nienaber U., Innerhofer P., Westermann I., et al. The impact of fresh frozen plasma vs coagulation factor concentrates on morbidity and mortality in trauma-associated haemorrhage and massive transfusion. Injury: 2011; 42 7 697 701
35. Joseph B., Amini A., Friese R. S., et al. Factor IX complex for the correction of traumatic coagulopathy. J Trauma Acute Care Surg: 2012; 72 4 828 834
36. Fries D. The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. Transfusion: 2013; 53 01 91S 95S
37. Sorensen B., Spahn D. R., Innerhofer P., Spannagl M., Rossaint R. Clinical review: Prothrombin complex concentrates-evaluation of safety and thrombogenicity. Crit Care: 2011; 15 R201
38. Palareti G., Leali N., Coccheri S., et al. Italian Study on Complications of Oral Anticoagulant Therapy. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet: 1996; 348 9025 423 428
39. Diness V., Lund-Hansen T., Hedner U. Effect of recombinant human FVIIA on warfarin-induced bleeding in rats. Thromb Res: 1990; 59 6 921 929
40. Erhardtsen E., Nony P., Dechavanne M., Ffrench P., Boissel J. P., Hedner U. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrinolysis: 1998; 9 8 741 748
41. Deveras R. AE, Kessler C. M. Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med: 2002; 137 11 884 888
42. Sorensen B., Johansen P., Nielsen G. L., Sorensen J. C., Ingerslev J. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis: 2003; 14 5 469 477
43. Rosovsky R. P., Crowther M. A. What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin? ASH evidence-based review 2008. Hematology (Am Soc Hematol Educ Program): 2008; ••• 36 38
44. Makris M., Greaves M., Phillips W. S., Kitchen S., Rosendaal F. R., Preston E. F. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost: 1997; 77 3 477 480
45. Cartmill M., Dolan G., Byrne J. L., Byrne P. O. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg: 2000; 14 5 458 461
46. Huttner H. B., Schellinger P. D., Hartmann M., et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke: 2006; 37 6 1465 1470
47. Woo C. H., Patel N., Conell C., et al. Rapid Warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate. World Neurosurg: 2014; 81 1 110 115
48. Imberti D., Barillari G., Biasioli C., et al. Emergency reversal of anticoagulation with a three-factor prothrombin complex concentrate in patients with intracranial haemorrhage. Blood Transfus: 2011; 9 2 148 155
49. Sarode R., Milling T. J. Jr, Refaai M. A., et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation: 2013; 128 11 1234 1243
50. Hickey M., Gatien M., Taljaard M., Aujnarain A., Giulivi A., Perry J. J. Outcomes of urgent warfarin reversal with frozen plasma versus prothrombin complex concentrate in the emergency department. Circulation: 2013; 128 4 360 364
51. Leissinger C. A., Blatt P. M., Hoots W. K., Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol: 2008; 83 2 137 143
52. Dentali F., Marchesi C., Pierfranceschi M. G., et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost: 2011; 106 3 429 438
53. Franchini M., Mannucci P. M. New anticoagulants for treatment of venous thromboembolism. Eur J Intern Med: 2012; 23 8 692 695
54. Mannucci P. M., Franchini M. Old and new anticoagulant drugs: a minireview. Ann Med: 2011; 43 2 116 123
55. Gross P. L., Weitz J. I. New antithrombotic drugs. Clin Pharmacol Ther: 2009; 86 2 139 146
56. Franchini M., Mannucci P. M. A new era for anticoagulants. Eur J Intern Med: 2009; 20 6 562 568
57. Ageno W., Gallus A. S., Wittkowsky A., Crowther M., Hylek E. M., Palareti G.; American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 2 e44S e88S
58. Dentali F., Riva N., Crowther M., Turpie A. G., Lip G. Y., Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation: 2012; 126 20 2381 2391
59. Van Ryn J., Litzenburger T., Waterman A., et al. Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models. J Am Coll Cardiol: 2011; 57 E1130
60. Lu G., DeGuzman F. R., Lakhotia S., Hollenbach S. J., Phillips D. R., Sinha U. Recombinant antidote for reversal of anticoagulation by factor Xa inhibitors. ASH Annual Meet Abstr: 2008; 112 983
61. Lu G. P., Peng L., Hollenbach S. J., et al. Reconstructed recombinant factor Xa as an antidote to reverse anticoagulation by factor Xa inhibitors. J Thromb Haemost: 2009; 7 309
62. Zhou W., Schwarting S., Illanes S., et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke: 2011; 42 12 3594 3599
63. Godier A., Miclot A., Le Bonniec B., et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology: 2012; 116 1 94 102
64. Escolar G., Arellano-Rodrigo E., Reverter J. C., et al. Reversal of apixaban induced alterations of hemostasis by different coagulation factor concentrates: studies in vitro with circulating human blood. Circulation: 2012; 126 520 521
65. Marlu R., Hodaj E., Paris A., Albaladejo P., Cracowski J. L., Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost: 2012; 108 2 217 224
66. Liew A., Eikelboom J. W., O'Donnell M., Hart R. G. Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants. Can J Cardiol: 2013; 29 7 S34 S44
67. Pragst I., Zeitler S. H., Doerr B., et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost: 2012; 10 9 1841 1848
68. Eerenberg E. S., Kamphuisen P. W., Sijpkens M. K., Meijers J. C., Buller H. R., Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation: 2011; 124 14 1573 1579
69. Perzborn E., Gruber A., Tinel H., et al. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost: 2013; 110 1 162 172
70. Escolar G., Arellano-Rodrigo E., Reverter J. C., et al. Reversal of apixaban induced alterations of hemostasis by different coagulation factor concentrates: studies in vitro with circulating human blood. Blood: 2012; 190 21 Abstract 2263
71. Arellano-Rodrigo E., Galan A. M., Sanz V., et al. Alterations induced by rivaroxaban on hemostasis can be reversed by different coagulation factor concentrates: in vitro experimental studies with steady and circulating human blood. J Thromb Haemost: 2013; 11 02 953
72. Khoo T. L., Weatherburn C., Kershaw G., Reddel C. J., Curnow J., Dunkley S. The use of FEIBA® in the correction of coagulation abnormalities induced by dabigatran. Int J Lab Hematol: 2013; 35 2 222 224
73. Escolar G., Fernandez-Gallego V., Arellano-Rodrigo E., et al. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. PLoS ONE: 2013; 8 11 e78696